American Pharmaceutical Companies and Global Health

| April 20, 2017

article image
Over the winter, the World Health Organization (WHO) published a list of twelve bacterial families, against which new antibiotics are needed urgently, based on current and emerging global health issues.

Spotlight

Pharmathen

Founded in 1969, the company has achieved significant milestones through an immaculate performance history, always upholding the highest ethical and operational standards, with compliance to regulatory affairs. Strongly dedicated to strategic planning and its vision, Pharmathen soon emerged as one of the largest independent generic development companies in Europe. With a pipeline of approximately ten generic molecules a year and vigorous export activities in over 80 countries, the company has reached export sales dynamics that amount to 70% of the group’s total annual sales.

OTHER ARTICLES

Tips for Managing Chronic Pain Beyond Prescription Painkillers

Article | February 17, 2020

Painkillers like Oxycontin, Percocet, and Vicodin, have been prescribed by primary physicians, surgeons, dentists, and other healthcare providers to patients suffering from varying levels of pain. Though these medications have proven to be an effective source of pain relief, they have also proven to be highly addictive. In fact, it has even been reported that there are more cases of a drug overdose and deaths from prescription painkillers than heroin or cocaine. While there are a number of factors that play into this opioid epidemic, educating doctors and patients on alternative solutions to managing chronic pain is a great place to start combatting this nationwide crisis.

Read More

Top Specialty Pharmacy Therapy Areas

Article | March 16, 2020

Accelerated by advancements in cancer treatments and a growing emphasis on personalized and precision medicine, specialty pharmacy represents a rapidly growing sector within the healthcare industry. In fact, the market is projected to grow to $500 billion by the end of this year—up from $200 billion in total U.S. specialty drug spending in 2017. Industry growth of this magnitude creates challenges for those looking to understand and penetrate the market. It can be difficult, after all, to maintain updated information about high-priority drug therapy areas or facility affiliations in a market that’s constantly changing.

Read More

Pharmacist eCare Plan - the newest disrupter in health data exchange?

Article | February 25, 2020

Every member of the health care team shares a common goal of optimizing patient outcomes. Yet each specialty and position of the healthcare team has a unique workflow facilitated by various tools, from an operative report to a progress note. In this regard the pharmacist plays a pivotal function in medication management and requires documentation specific to that role. The Pharmacist eCare Plan (PeCP) allows for an interoperable note to be used in the pharmacy to assist in the exchange of patient information, including active medication list, laboratory results, and payer information. To allow for this, a new type of clinical document architecture for the PeCP was created and standardized for use across pharmacies.

Read More

Pfizer Won’t Win the Coronavirus Pharma War

Article | March 6, 2020

Shares of Pfizer jumped more than 6% on Wednesday, after the company announced a plan to test some of its antiviral products as a potential treatment for the coronavirus from China. More than 35 million shares traded on the news — about 48% more than normal — as investors looked for any positive news from the pharma community after the recent selloff. So, does this mean that Pfizer stock is turning the corner?

Read More

Spotlight

Pharmathen

Founded in 1969, the company has achieved significant milestones through an immaculate performance history, always upholding the highest ethical and operational standards, with compliance to regulatory affairs. Strongly dedicated to strategic planning and its vision, Pharmathen soon emerged as one of the largest independent generic development companies in Europe. With a pipeline of approximately ten generic molecules a year and vigorous export activities in over 80 countries, the company has reached export sales dynamics that amount to 70% of the group’s total annual sales.

Events